吲哚美辛预防髋臼骨折术后异位骨化的疗效分析

[目的]探讨吲哚美辛在预防髋臼骨折术后异位骨化中的作用。[方法]回顾性分析本院自2009年1月~2012年1月收治的120例采用Kocher-Langenbeck入路治疗的髋臼骨折病例,将上述患者随机分为两组,无药物组患者60例,术后无任何药物干预,吲哚美辛组患者60例,术后1d开始口服吲哚美辛,25 mg/次,3次/d,持续4周;术后门诊随访X线片并记录异位骨化发生情况,随访时间最短6个月,最长18个月。[结果]在所有的患者中,异位骨化发生率为49%,其中Brooker Ⅰ级16例,Ⅱ级18例,Ⅲ级15例,Ⅳ级10例,18例患者有症状,4例需要再次手术。吲哚美辛组与无药物组相比,轻度异位骨化发生率明显降低,但重度异位骨化的发生率无明显差异。[结论]髋臼骨折术后应用吲哚美辛并不能有效预防重度异位骨化的发生,应提高医生手术技巧,降低发生率。     

吲哚美辛预防髋臼骨折术后异位骨化的临床研究

目的通过服用吲哚美辛预防髋臼骨折术后异位骨化(HO)的发生以了解非甾体类抗炎药抑制HO形成的效果。方法对2001年2月～2003年8月采用Kocher-Langenbeck(K-L)入路治疗并在术后服用吲哚美辛的50例髋臼骨折患者进行随访研究(用药组),其结果与1993年3月～1998年5月采用相同后入路治疗而在术后未服用吲哚美辛的40例髋臼骨折患者进行对照研究(对照组)。用药组患者从术后第1天开始口服吲哚美辛,25 mg/次,3次/d,应用4周。术后定期对患者进行复杏。随访术后HO的发生情况,并对所有患者进行临床功能评价。结果用药组48例患者获完整资料随访,平均随访时间为22．8个月(6～39个月)。8例患者发生HO,据Brooker分型：Ⅰ度5例,Ⅱ度3例,尤严重HO(Ⅲ、Ⅳ度)发生；HO的发生率为16．7。对照组40例患者获平均26．4个月(4～58个月)随访。14例患者发生HO,HO发生率为35．0%,其中4例为严重HO。两组患者HO和严重HO的发生率差异均有显著性意义(P＜0．05)。结论吲哚美辛对髋臼骨折术后HO形成有一定的预防作用。     

吲哚美辛对ERCP术后高淀粉酶血症及胰腺炎的预防作用

目的观察常规直肠应用吲哚美辛栓剂对内镜下逆行胰胆管造影术(endoscopic rectrograde cholangiopancreatography,ERCP)术后高淀粉酶血症、胰腺炎的预防作用。方法回顾性分析2009年1月至2014年12月,池州市人民医院消化内镜中心行ERCP治疗的166例临床患者资料,其中术前预防性使用吲哚美辛栓纳肛的病例94例,未使用吲哚美辛72例,比较两组ERCP术前、术后3 h、术后24 h血清淀粉酶水平及术后高淀粉酶血症、胰腺炎的发生率。结果 2组患者术前血淀粉酶无统计学差异(78.0±6.9 vs 87.8±7.8,P0.05),但吲哚美辛组术后3 h血淀粉酶水平显著低于对照组(175.6±67.7 vs438.6±77.4,P0.01),24 h血淀粉酶也低于对照组(227.8±37.3 vs 239.8±38.1,F=19.93,P0.01)。吲哚美辛纳肛组ERCP术后高淀粉酶血症发生率低于对照组(3.2%vs 5.6%,P0.01),吲哚美辛纳肛组ERCP术后胰腺炎发生率也低于对照组(7.4%vs 12.5%,P0.01)。结论 ERCP术前使用吲哚美辛可以预防ERCP术后高淀粉酶血症及术后急性胰腺炎的发生,可以作为常规预防手段使用。     

吲哚美辛栓预防ERCP术后胰腺炎及高淀粉酶血症临床效果研究

目的观察并比较吲哚美辛栓预防经内镜逆行性胰胆管造影术(ERCP)后胰腺炎及高淀粉酶血症的临床效果。方法将2013年6月~2015年6月间本院内镜中心收治的204例接受ERCP诊治患者随机分为2组:吲哚美辛组于术前30min经直肠给与吲哚美辛栓剂100mg,对照组不予任何预防药物。检测所有患者术前、术后6h、12h、24 h血清淀粉酶水平,比较2组患者ERCP术后胰腺炎(PEP)和高淀粉酶血症发生率,观察不良反应。结果 2组患者ERCP术前血清淀粉酶均为正常值。术后6h、12h、24h血清淀粉酶水平与术前比较均升高,两组差异有统计学意义(P0.05)。吲哚美辛栓组、对照组PEP发生率分别为4.00%、18.37%,差异有统计学意义(χ~2=3.810,P0.05);吲哚美辛组、对照组ERCP术后高淀粉酶血症发生率分别为32.00%、55.10%,差异有统计学意义(χ~2=5.437,P0.05)。吲哚美辛组未出现严重不良反应。结论 ERCP术前预防性直肠应用吲哚美辛栓可有效降低PEP和高淀粉酶血症的发生率,且安全性好。     

应用吲哚美辛栓预防经内镜逆行胰胆管造影术后高淀粉酶血症及胰腺炎的作用

目的探讨经内镜逆行胰胆管造影术(ERCP)应用吲哚美辛栓对预防术后高淀粉酶血症及胰腺炎的作用。方法将医院106例行ERCP者作为此次研究对象,按照随机数字表法将其分组为对照组与观察组,各53例。对照组术后不给予抑制胰腺分泌药物,观察组术后给予吲哚美辛栓。分别于术前、术后3h、24h检测两组血清淀粉酶水平,记录两组术后高淀粉酶血症、胰腺炎发生人数。结果两组患者术后3h、24h血清淀粉酶水平明显高于术前,然观察组术后3h、24h明显低于对照组比较,P0.05。观察组术后高淀粉酶血症、胰腺炎发生率分别为5.66%(3/53)、7.55%(4/53),明显低于对照组32.08%(17/53)、18.87%(10/53),P0.05。结论经内镜逆行胰胆管造影术(ERCP)患者术后应用吲哚美辛栓可有效预防急性胰腺炎的发生。     

右旋酮洛芬氨丁三醇在慢性前列腺炎/慢性骨盆疼痛综合征治疗中的应用

目的:评价右旋酮洛芬氨丁三醇在治疗慢性前列腺炎/慢性骨盆疼痛综合征(CP/CPPS)中的疗效和安全性。方法:115例CP/CPPS患者被随机分为3组,右旋酮洛芬氨丁三醇组40例,口服右旋酮洛芬氨丁三醇25mg,3次/d,特拉唑嗪2mg,1次/晚;吲哚美辛组40例,口服吲哚美辛25mg,3次/d,特拉唑嗪2mg,1次/晚;特拉唑嗪组35例,口服特拉唑嗪2mg,1次/晚,分别连续药物治疗4周。治疗前后分别进行NIH-CPSI评分,比较各组的疗效和不良反应发生率。结果:治疗后各组NIH-CPSI评分较治疗前有明显改善,右旋酮洛芬氨丁三醇组和吲哚美辛组疗效均优于特拉唑嗪组(P<0.05),但其两组之间疗效相比差异无显著性(P>0.05)。右旋酮洛芬氨丁三醇组、吲哚美辛组和特拉唑嗪组不良反应发生率分别为10.00%、27.50%、8.57%,右旋酮洛芬氨丁三醇组、特拉唑嗪组不良反应发生率分别与吲哚美辛组相比差异有显著性(P<0.05)。结论:右旋酮洛芬氨丁三醇联合特拉唑嗪能有效改善CP/CPPS症状,其疗效优于单用特拉唑嗪,耐受性优于吲哚美辛。     

吲哚美辛栓外用于PPH术后的疗效观察

目的 观察PPH术后,吲哚美辛栓外用对术后Ⅲ度疼痛及尿潴留并发症的临床疗效.方法 将2007年12月前我科PPH手术病例40例作为对照组,2007年12月至2008年3月19例病例作为治疗组,术后将吲噪美辛栓1粒纳入肛内,观察术后并发症的情况,并进行统计学分析.结果 治疗组术后疼痛和尿潴留等并发症明显减少.结论 PPH术后外用吲哚美辛栓可减轻疼痛及降低尿潴留并发症的发生率.     

托特罗定联合吲哚美辛栓剂治疗前列腺术后膀胱痉挛临床观察

目的观察托特罗定联合吲哚美辛栓剂治疗前列腺术后膀胱痉挛临床疗效。方法回顾性分析,将89例前列腺增生术后膀胱痉挛患者随机分为对照组和实验组,对照组患者手术当日口服托特罗定2 mg,2次/d,于拔除导尿管前1 d停药;实验组患者手术当日口服托特罗定2 mg,2次/d,加上吲哚美辛直肠栓剂50 mg纳肛,2次/d,于拔除导尿管前1 d停药。结果实验组在术后72h内膀胱痉挛的发作次数,膀胱痉挛持续时间、膀胱冲洗时间、膀胱冲洗液转清时间均明显优于对照组。结论托特罗定联合吲哚美辛栓剂治疗前列腺术后膀胱痉挛的疗效显著,优于单独应用托特罗定治疗膀胱痉挛的效果。     

补阳还五汤加味预防全髋关节置换术后异位骨化

目的:探讨补阳还五汤加味预防全髋关节置换术后异位骨化的效果。方法:将有完整记录的93例行人工全髋关节置换术患者前瞻性分为两组,A组术后口服补阳还五汤,B组不服用任何药物,手术前后进行放射检查(包括骨盆正位、髋关节侧位片,必要时CT检查)及髋关节功能评估,观察有无异位骨化形成,骨化程度采用Brooker分级法评定,髋关节功能评分按照Harris评分。结果:本组93例随访平均16.7个月,根据Brook分级,A组异位骨化发生率20%,B组43.75%;术后Harris评分A组(89.17±15.36),B组(84.00±12.05),差异有统计学意义。结论:补阳还五汤加味可明显减少全髋关节置换术后异位骨化的发生率。     

序贯应用地塞米松及吲哚美辛栓剂防治Wilson病脾切除术后发热

目的 观察地塞米松联合吲哚美辛栓剂序贯用药防治肝豆状核变性合并脾功能亢进(脾亢)病人术后发热的疗效及并发症.方法 分析1995年1月至2007年1月,小剂量地塞米松联合吲哚美辛栓剂序贯用药,防治45例肝豆状核变性病人脾切除术后发热,并与对照组42例进行比较.结果 治疗组术后1周内体温恢复正常者42例(93.3%),术后2周内体温全部恢复正常(100%),发生各种并发症5例(11.1%);对照组术后1周内体温恢复正常者26例(61.9%),术后2周内共32例(76.2%),发生各种并发症12例(28.6%).结论 肝豆脾切除术后序贯应用地塞米松及吲哚美辛栓剂防治发热疗效确切(P＜0.01)且能显著降低术后并发症(P＜0.01).     

多孔双相陶瓷复合重组人骨形态发生蛋白-2和碱性成纤维细胞生长因子缓释微球的异位成骨活性

目的 观察复合重组人骨形态发生蛋白-2(rhBMP-2)和碱性成纤维细胞生长因子(bFGF)缓释微球的多孔双相陶瓷(BCP)异位成骨活性.方法 A组(rhBMP-2+bFGF缓释微球/BCP)、B组(BCP)、C组(bFGF缓释微球/BCP)、D组(rhBMP-2缓释微球/BCP),其中bFGF和rhBMP的浓度各为5、15μg.规格均为3mm×8mm×28mm.将材料植入兔背部肌袋内,术后4、8、12周分别取材,行大体、组织学观察,测量新骨面积和血管生成.结果 8、12周A组成骨活性较其他组优,差异有统计学意义 (P<0.05).A组4周材料中有较多间充质细胞,并有少量毛细血管的生长;8周时可见散在分布的不成熟新生骨组织,材料基本降解;12周时出现成熟度较低的编织骨,为膜内成骨.结论 BCP复合rhBMP-2和bFGF缓释微球具有良好的异位成骨活性.

Abstract：

Objective To investigate the heterotopic bone formation ability of biphasic ceramics phosphate (BCP) combined with recombinant human bone morphogenetic protein-2 (rhBMP-2) and basic fibroblast growth factor (bFGF) microspheres.Methods The rabbits were divided into group A (rhBMP-2+bFGF/BCP), group B (BCP), group C (bFGF/BCP), and group D (rhBMP-2/BCP). The concentrations of bFGF and rhBMP were 5 μg and 15 μg, respectively. All the samples were 3 mm×8 mm×28 mm in size. The muscle pouches of the rabbits were implanted with the samples. The ectopic bone formation was evaluated in the following aspects: histology, osteogenic area, and blood capillary number at 4th, 8th and 12th week after operation.Results At any specified time point, the value of the heterotopic bone formation was significantly higher in group A than other groups (P< 0.05). The histological analysis showed that group A had more mesenchymal (MES) cells and fewer blood capillaries at 4th week after operation. At 8th week, the composite was degradated and diffusely distributed, and the immature new bone was found. There were low-grade mature woven bones at 12th week, and the membranous bone formation occurred.Conclusion BCP combined with rhBMP-2 and bFGF microspheres has good heterotopic bone formation ability.     

Influence of indomethacin on induced heterotopic bone formation in rats. Importance of length of treatment and of age

The effect of indomethacin on heterotopic and orthotopic bone formation in rats was analyzed with respect to (1) length of treatment after implantation, (2) duration of the indomethacin induced inhibition of heterotopic bone formation, and (3) influence of age of the implant recipient. Three weeks after implantation of demineralized bone matrix, the ash weight of implants from rats receiving indomethacin 2 mg/kg body weight during the entire experiment was 31% lower than that of controls. Animals treated for only six days after implantation exhibited an almost equally pronounced inhibition. However, six weeks after implantation, the inhibition caused by six days of indomethacin treatment had almost dissipated. In older rats the implants of demineralized bone matrix induces smaller volumes of new bone than in younger rats, but indomethacin causes approximately the same degree of inhibition of osteoinduction. Orthotopic bone is not affected by indomethacin treatment. This study shows that a short period of indomethacin treatment at the time of implantation of demineralized bone matrix is sufficient to reduce experimental bone formation, but the inhibitory effect slowly diminishes if the inductive process is continuous. The results indicate that the inhibition of heterotopic new bone formation by indomethacin may be mediated through reduction of the initial inflammatory response or by reduced mesenchymal cell proliferation.     

The use of indomethacin to prevent the formation of heterotopic bone after total hip replacement. A randomized, double-blind clinical trial

We studied the effect of indomethacin on the prevention of formation of heterotopic bone after total hip replacement. In a randomized, double-blind clinical trial involving 201 patients, 102 patients received twenty-five milligrams of indomethacin three times daily for the first six postoperative weeks, and the other ninety-nine patients received a placebo. One year after the operation, eighty-nine of those who had received indomethacin had no sign of heterotopic ossification, and the remaining thirteen had a grade-I lesion. In the group that had received a placebo, twenty-seven had no heterotopic ossification; twenty-four, a grade-I lesion; thirty, a grade-II lesion; and eighteen, a grade-III lesion. Significantly fewer patients who had received indomethacin had formation of heterotopic bone compared with those who had been given a placebo (chi-square test, p less than 0.0005). Only patients who had grade-III formation of heterotopic bone had a significant reduction in movement of the hip.     

Traumatic heterotopic bone formation in the quadriceps muscle: No progression by continuous passive motion in rabbits

One hind limb in each of 20 New Zealand White rabbits was immobilized for 3 weeks together with daily forcible manipulation to induce heterotopic bone formation in the quadriceps muscle. the rabbits were then divided equally into a control group and a group treated with continuous passive motion (CPM). the effect of CPM on the development of heterotopic bone formation was assessed by radiographs of the femur and by histology. Treatment with CPM did not lead to increased heterotopic bone formation, as compared to the control group.     

Surgical excision of heterotopic bone after hip surgery followed by oral indomethacin application: is there a clinical benefit for the patient?

The clinical effect of surgical excision of heterotopic bone after hip surgery in combination with an oral indomethacin application was analysed in 21 patients in a retrospective study. Indomethacin (3 x 50 mg) was administered after the first postoperative day for a period of 6 weeks. To avoid gastrointestinal side-effects, a mucoprotectivum (sucralfat, 3 x 1 g) was also applied. One year after surgery, 19 patients (90.4%) had excellent relief of pain, the average improvement of flexion was 40 degrees, of abduction 13 degrees, of internal rotation 8 degrees and of external rotation 14 degrees. Only one patient (4.8%) suffered a recurrence of heterotopic bone formation, and in one patient (4.8%) we observed gastrointestinal side-effects. Thus, we recommend surgical excision of heterotopic bone followed by oral indomethacin therapy as a convenient and reliable strategy to prevent new heterotopic bone formation after hip surgery.     

Indomethacin compared with localized irradiation for the prevention of heterotopic ossification following surgical treatment of acetabular fractures.

BACKGROUND: There is controversy surrounding the relative effectiveness of local irradiation and oral indomethacin for prophylaxis against heterotopic ossification following surgical treatment of acetabular fractures. The purpose of this study was to compare the efficacy of these two commonly used methods in a prospective, randomized trial. METHODS: From July 1992 to June 1999, 166 patients in whom a fracture of the acetabulum was treated surgically through a posterior, extensile, or combination approach were randomized to receive either indomethacin or radiation therapy postoperatively. Seventy-eight patients received 800 cGy of local radiation therapy within seventy-two hours after surgery, and seventy-two patients received a six-week course of indomethacin (25 mg three times a day) beginning within twenty-four hours after surgery. Sixteen additional patients were randomized but did not receive treatment with either prophylactic regimen. At an average of fourteen months, the extent of heterotopic ossification was assessed on plain radiographs with use of the classification of Brooker et al. The grade of ossification was correlated with hip motion. RESULTS: There was no significant difference between treatment groups with regard to patient age, gender, Glasgow Coma Scale, operative time, estimated operative blood loss, duration of follow-up, or presence of closed head injury. The Injury Severity Score appeared to be the only covariate that was significantly different between the groups (p = 0.019). Grade-III or IV ossification developed in eight (11%) of the patients in the indomethacin group and three (4%) in the radiation therapy group. The difference was not significant (p = 0.22; 95% confidence interval, -1.1%, +15.7%). No complications related to the prophylaxis were noted in either group. Heterotopic ossification developed in all sixteen patients who did not receive prophylaxis, with six demonstrating grade-III or IV changes. The overall prevalence of grade-III or IV heterotopic ossification was 7% (eleven of 150) in the treated groups and 38% (six of sixteen) in the untreated group. We did not find any association between the prevalence of heterotopic ossification and fracture type (p = 0.296) or posterior hip dislocation (p = 0.306). Grade-I, II, and III heterotopic ossification did not decrease the range of motion of the hip except in flexion. CONCLUSIONS: Both local radiation therapy and indomethacin were found to provide effective prophylaxis against heterotopic ossification following surgical treatment of acetabular fractures through a posterior or extensile approach. We detected no significant difference in efficacy between the two prophylactic regimens.     

The influence of indomethacin on biomechanical and biochemical properties of the plantaris longus tendon in the rabbit

It has previously been reported that indomethacin inhibits fracture healing and heterotopic bone formation. Stimulated by these reports, we undertook the present investigation to study the influence of indomethacin on biomechanical and biochemical properties of the plantaris longus tendon in the rabbit. Sixty-eight New Zealand White rabbits were used for the experiment. Half of them were treated with indomethacin, 10 mg/kg orally a day, and the other half with placebo. After 4, 8, and 16 weeks of treatment biomechanical and biochemical variables were determined and compared between the two groups. After 16 weeks there was a significant increase in tensile strength in the group treated with indomethacin. There was no certain concomitant change in the total collagen content, the amounts of soluble and insoluble collagen, or the water content. Further investigations concerning the influence of indomethacin on tendon healing are indicated.     

Inhibition of heterotopic osteogenesis in rats by a new bioerodible system for local delivery of indomethacin.

A study was done to evaluate the effect of a system for the local delivery of indomethacin on demineralized bone-induced formation of heterotopic bone in the abdominal muscles of rats. Two separate investigations were conducted on a total of forty-eight Wistar rats. In both series, two types of implants were used: polyorthoester and demineralized bone (Group A, the control group) and polyorthoester with 5 per cent indomethacin and demineralized bone (Group B, the experimental group). In the first series, host-tissue responses and osteoinduction were evaluated histologically at two, three, and four weeks after the implantation. In the second series, the formation of bone was quantified on the basis of uptake of 85Sr at four weeks after the implantation. The polyorthoester system for the local delivery of indomethacin significantly inhibited demineralized bone-induced heterotopic formation of bone, as demonstrated by light microscopy and by uptake of 85Sr. The polyorthoester, with or without the drug, caused little tissue reaction and was resorbed almost completely at four weeks.     

Optimal treatment of fibrodysplasia ossificans progressiva with surgical excision of heterotopic bone, indomethacin, and irradiation

A case report is presented of an 18-year-old boy with advanced fibrodysplasia ossificans progressiva. The patient's right hip was ankylosed in 35 degrees of flexion. Excision of the heterotopic bone from the right hip was followed by a combination of a single fraction irradiation (7Gy) given in the first postoperative day, and an 11-day treatment with indomethacin (25 mg, three times daily, orally). One year postoperatively, the patient ambulates nearly normally and he is able to sit and stand up without significant difficulty. Radiographs of the right hip showed a small amount of heterotopic bone formation at the operative site. In contrast with the results published in the literature, the clinical result of the operation is considered satisfactory. Further investigation of the combined use of indomethacin and single fraction irradiation as a preventive measure after surgical excision of heterotopic bone in patients with fibrodysplasia ossificans progressiva FOP should be performed.     

Influence of indomethacin on experimental bone metabolism in rats

The effect of indomethacin on heterotopic and orthotopic bone formation in rats was analyzed with respect to dose and time of initiation of drug administration. Three weeks after implantation of demineralized bone matrix, the ash weight of implants from animals receiving the highest doses of indomethacin was approximately 25% lower than that of controls. The ash weight of implants was only affected in rats receiving indomethacin from the week before implantation or from the time of implantation. In a separate study, no effect on the rate of resorption measured by elimination of 3H-proline and 45Ca or on the amount of ash could be detected. Orthotopic bone remained unaffected by indomethacin treatment. The study showed that in order to inhibit experimental new bone formation, indomethacin must be present before or at the time of implantation of demineralized bone matrix.